Contributors |
|
xv | |
Preface |
|
xxiil | |
Volumes in Series |
|
xxv | |
|
Section I Inverse Agonism and Inverse Agonists |
|
|
1 | (274) |
|
1 Identification and Characterization of Steroidogenic Factor-1 Inverse Agonists |
|
|
3 | (22) |
|
|
|
|
|
|
4 | (2) |
|
2 Characterization of Inverse Agonists of SF-1 by uHTS |
|
|
6 | (11) |
|
3 Effect of SF-1 Inverse Agonists on Adrenocortical Tumor Cell Proliferation and Sterold Production |
|
|
17 | (3) |
|
|
20 | (2) |
|
|
22 | (1) |
|
|
22 | (3) |
|
2 Assessment of Inverse Agonism for the Angiotensin II Type 1 Receptor |
|
|
25 | (12) |
|
|
|
|
|
|
26 | (1) |
|
2 Protocol for Cell Culture and Transfection |
|
|
26 | (1) |
|
3 Radioligand Assay for AT1 Receptor |
|
|
27 | (1) |
|
4 Protocol for Cell Stretching |
|
|
28 | (2) |
|
5 Assessment of AT1 Receptor Activation |
|
|
30 | (3) |
|
|
33 | (1) |
|
|
34 | (1) |
|
|
34 | (3) |
|
3 Measurement of Inverse Agonism in β-Adrenoceptors |
|
|
37 | (24) |
|
|
|
|
1 Introduction: Basal Spontaneous Receptor Activity. The Rise of the Concept of Inverse Agonism |
|
|
38 | (4) |
|
2 β-Adrenoceptors: Main Features |
|
|
42 | (3) |
|
3 Methodological Aspects of the Assessment of Inverse Agonist Properties at βAR |
|
|
45 | (6) |
|
4 Clinical Potential Uses of βAR Inverse Agonists |
|
|
51 | (2) |
|
|
53 | (8) |
|
4 Techniques for Studying Inverse Agonist Activity of Antidepressants at Recombinant Nonedited 5-HT2C-INI Receptor and Native Neuronal 5-HT2C Receptors |
|
|
61 | (20) |
|
|
|
|
|
62 | (3) |
|
2 Constitutive Activity Toward the Gαq-PLC Effector Pathway of 5-HT2C-INI Receptors Transiently Expressed in HEK-293 Cells |
|
|
65 | (6) |
|
3 Plasma Membrane Insertion of 5-HT2C-INI Receptors |
|
|
71 | (2) |
|
4 Enhanced Responsiveness of Constitutively Active 5-HT2C Receptors Upon Prolonged Treatment with Inverse Agonists |
|
|
73 | (4) |
|
|
77 | (1) |
|
|
77 | (4) |
|
5 Differential Inverse Agonism at the Human Muscarinic M3 Receptor |
|
|
81 | (22) |
|
|
|
|
1 Introduction to Muscarinic Receptors |
|
|
82 | (2) |
|
2 Role of M3R in Regulating Smooth Muscle Function and Clinical Use of Anticholinergics |
|
|
84 | (1) |
|
3 In Vitro Assays to Monitor hM3R Activation and Constitutive Activity |
|
|
85 | (10) |
|
4 Constitutive Activity and Receptor Upregulation Studies |
|
|
95 | (3) |
|
5 Physiological Relevance of hM3R Constitutive Activity |
|
|
98 | (2) |
|
|
100 | (3) |
|
6 Ghrelin Receptor: High Constitutive Activity and Methods for Developing Inverse Agonists |
|
|
103 | (20) |
|
|
Annette G. Beck-Sickinger |
|
|
|
|
104 | (1) |
|
2 Constitutive Activity and Development of Ghrelin Receptor Inverse Agonists |
|
|
105 | (2) |
|
3 Synthesis of Ghrelin Receptor Inverse Agonists: Solid-Phase Peptide Synthesis (SPPS) |
|
|
107 | (6) |
|
4 Functional Assays for Ghrelin Receptor Inverse Agonists |
|
|
113 | (6) |
|
|
119 | (4) |
|
7 Constitutive Activity and Inverse Agonism at the α1a and α1b Adrenergic Receptor Subtypes |
|
|
123 | (16) |
|
|
|
124 | (3) |
|
2 Combination of Computational Modeling and Site-Directed Mutagenesis of the Receptor to Identify Constitutively Activating Mutations |
|
|
127 | (3) |
|
3 Measuring Constitutive Activity of Receptor-Mediated Gq Activation |
|
|
130 | (2) |
|
4 Inverse Agonism at the α1-ARs |
|
|
132 | (3) |
|
|
135 | (1) |
|
|
136 | (1) |
|
|
136 | (3) |
|
8 Measurement of Inverse Agonism of the Cannabinoid Receptors |
|
|
139 | (8) |
|
|
|
139 | (1) |
|
|
140 | (2) |
|
|
142 | (1) |
|
4 Electrophysiological Assays |
|
|
143 | (1) |
|
|
143 | (1) |
|
|
144 | (3) |
|
9 Constitutively Active Thyrotropin and Thyrotropin-Releasing Hormone Receptors and Their Inverse Agonists |
|
|
147 | (14) |
|
|
|
|
|
148 | (1) |
|
2 TRH-R2 and Its Inverse Agonist Midazolam |
|
|
149 | (4) |
|
3 TSHR and Its Inverse Agonist NCGC00161856 |
|
|
153 | (6) |
|
|
159 | (1) |
|
|
159 | (2) |
|
10 Inverse Agonists and Antagonists of Retinoid Receptors |
|
|
161 | (36) |
|
|
|
|
|
162 | (2) |
|
2 Functional Classification of Retinoid Receptor Ligands |
|
|
164 | (1) |
|
3 Structural Basis of Retinoid Receptor Action |
|
|
165 | (4) |
|
4 Synthetic Routes and Toolbox for Rational Retinoid Design |
|
|
169 | (8) |
|
5 Protocols for the Study of Ligand Function |
|
|
177 | (13) |
|
|
190 | (1) |
|
|
191 | (1) |
|
|
192 | (5) |
|
11 γ-Aminobutyric Acid Type A (GABAA) Receptor Subtype Inverse Agonists as Therapeutic Agents in Cognition |
|
|
197 | (16) |
|
|
|
|
198 | (5) |
|
2 Inverse Agonism: Definition |
|
|
203 | (1) |
|
3 Negative Allosteric Regulators of GABAA-R in Cognitive Impairment |
|
|
204 | (2) |
|
4 Methods for Evaluating the Affinity and Efficacy at GABAA Receptor Subtypes |
|
|
206 | (2) |
|
|
208 | (1) |
|
|
208 | (5) |
|
12 Assays for Inverse Agonists in the Visual System |
|
|
213 | (12) |
|
|
|
214 | (4) |
|
|
218 | (1) |
|
|
219 | (1) |
|
4 Transducin Activation Assay |
|
|
219 | (2) |
|
|
221 | (1) |
|
|
221 | (4) |
|
13 Receptor-Driven Identification of Novel Human A3 Adenosine Receptor Antagonists as Potential Therapeutic Agents |
|
|
225 | (20) |
|
|
|
|
|
|
226 | (1) |
|
2 Newer Potential Therapeutic Role of A3 Adenosine Receptors |
|
|
226 | (2) |
|
3 A3 Adenosine Receptor Antagonists |
|
|
228 | (3) |
|
4 Receptor-Based Antagonist Design |
|
|
231 | (12) |
|
|
243 | (1) |
|
|
243 | (2) |
|
14 Inverse Agonist Activity of Steroidogenic Factor SF-1 |
|
|
245 | (16) |
|
|
|
|
246 | (1) |
|
2 SF-1 Inverse Agonism in the R-SAT® Assay of Cellular Proliferation |
|
|
247 | (4) |
|
3 SF-1 Inverse Agonism in Luciferase Transcriptional Assay |
|
|
251 | (3) |
|
4 SF-1 Inverse Agonism in Adrenocortical Cultures |
|
|
254 | (3) |
|
|
257 | (1) |
|
|
257 | (4) |
|
15 Methods to Measure G-Protein-Coupled Receptor Activity for the Identification of Inverse Agonists |
|
|
261 | (14) |
|
|
|
|
|
262 | (4) |
|
2 [ 35S]GTPγS Binding Assay in Membrane Homogenates |
|
|
266 | (4) |
|
3 [ 35S]GTPγS Autoradiography in Brain Sections |
|
|
270 | (2) |
|
|
272 | (1) |
|
|
273 | (2) |
|
Section II Novel Strategies and Techniques for Constitutive Activity and Inverse Agonism |
|
|
275 | (336) |
|
16 Use of Pharmacoperones to Reveal GPCR Structural Changes Associated with Constitutive Activation and Trafficking |
|
|
277 | (16) |
|
|
|
|
278 | (1) |
|
2 Methods for Measuring Receptors and Receptor Activity |
|
|
279 | (4) |
|
|
283 | (7) |
|
|
290 | (1) |
|
|
290 | (1) |
|
|
290 | (3) |
|
17 Application of Large-Scale Transient Transfection to Cell-Based Functional Assays for Ion Channels and GPCRs |
|
|
293 | (18) |
|
|
|
|
|
|
|
|
294 | (1) |
|
2 Large-Scale Transient Transfection |
|
|
295 | (1) |
|
3 Cryopreservation of Cells |
|
|
296 | (1) |
|
4 Application to Ion Channel Assays |
|
|
297 | (8) |
|
5 Application to GPCR Assays |
|
|
305 | (3) |
|
|
308 | (1) |
|
|
309 | (1) |
|
|
309 | (2) |
|
18 Quantification of RNA Editing of the Serotonin 2C Receptor (5-HT2CR) Ex Vivo |
|
|
311 | (18) |
|
|
|
|
|
1 RNA Editing of the 5-HT2CR |
|
|
312 | (2) |
|
2 Functional Properties of 5-HT2CR Edited Isoforms |
|
|
314 | (1) |
|
3 Current Methods for Quantification of 5-HT2CR Editing Events Ex Vivo |
|
|
315 | (3) |
|
4 Quantification of 5-HT2CR Editing Events Ex Vivo with qRT-PCR |
|
|
318 | (7) |
|
|
325 | (1) |
|
|
325 | (4) |
|
19 Strategies for Isolating Constitutively Active and Dominant-Negative Pheromone Receptor Mutants in Yeast |
|
|
329 | (20) |
|
|
|
|
330 | (2) |
|
2 Selecting a Yeast Strain and Expression Vector |
|
|
332 | (3) |
|
3 Transforming Plasmids into Yeast |
|
|
335 | (2) |
|
4 "Gap-Repair" Approach for Targeting Mutagenesis to Genes on Plasmids |
|
|
337 | (1) |
|
5 Isolation of Constitutively Active Mutants |
|
|
338 | (4) |
|
6 Isolation of Dominant-Negative Mutants |
|
|
342 | (2) |
|
7 Further Methods for Analysis of Mutant Receptors |
|
|
344 | (3) |
|
|
347 | (1) |
|
|
347 | (2) |
|
20 Development of a GPR23 Cell-Based β-Lactamase Reporter Assay |
|
|
349 | (20) |
|
|
|
|
350 | (2) |
|
|
352 | (5) |
|
3 Development of a Cell-Based β-Lactamase Reporter Assay for Constitutively Active GPR23 |
|
|
357 | (5) |
|
4 Identification of GPR23 Inverse Agonists Using a β-Lactamase Reporter Screen |
|
|
362 | (3) |
|
|
365 | (1) |
|
|
366 | (1) |
|
|
366 | (3) |
|
21 Computational Modeling of Constitutively Active Mutants of GPCRs: C5a Receptor |
|
|
369 | (24) |
|
|
|
|
370 | (1) |
|
2 Modeling CAMs Based on Experimental Data for the Ground and Activated States of GPCRs |
|
|
371 | (6) |
|
3 Rotational Sampling of the TM Regions of GPCRs |
|
|
377 | (5) |
|
4 Modeling Structural Mechanisms of Constitutive Activity in C5aRs |
|
|
382 | (5) |
|
5 Conclusions and Perspectives |
|
|
387 | (1) |
|
|
387 | (1) |
|
|
387 | (6) |
|
22 TSH Receptor Monoclonal Antibodies with Agonist, Antagonist, and Inverse Agonist Activities |
|
|
393 | (28) |
|
|
|
|
|
|
394 | (3) |
|
2 Production of Monoclonal Antibodies to the TSHR with the Characteristics of Patient Serum Autoantibodies |
|
|
397 | (2) |
|
3 Characterization of 5C9 a Human Autoantibody with TSH Antagonist and TSHR Inverse Agonist Activity |
|
|
399 | (6) |
|
4 Effects of TSHR Mutations on the Activity of MAb 5C9 |
|
|
405 | (7) |
|
5 Structure of MAb 5C9 Fab |
|
|
412 | (3) |
|
|
415 | (1) |
|
|
416 | (1) |
|
|
417 | (4) |
|
23 Current Standards, Variations, and Pitfalls for the Determination of Constitutive TSHR Activity In Vitro |
|
|
421 | (16) |
|
|
|
|
|
422 | (3) |
|
2 Detection of Constitutive TSHR Activity |
|
|
425 | (4) |
|
3 Methods and Required Materials for LRA |
|
|
429 | (3) |
|
|
432 | (1) |
|
|
433 | (1) |
|
|
433 | (4) |
|
24 Toward the Rational Design of Constitutively Active KCa3.1 Mutant Channels |
|
|
437 | (22) |
|
|
|
|
|
|
438 | (3) |
|
2 Production of Constitutively Active KCa3.1 Mutant Channels |
|
|
441 | (13) |
|
|
454 | (1) |
|
|
455 | (4) |
|
25 Fusion Proteins as Model Systems for the Analysis of Constitutive GPCR Activity |
|
|
459 | (22) |
|
|
|
|
460 | (2) |
|
2 Expression of Fusion Proteins: hH4R-Gα12 and hH4R-GAIP as Paradigms |
|
|
462 | (4) |
|
3 Investigation of GPCR Constitutive Activity with Fusion Proteins: H4R as Paradigm |
|
|
466 | (10) |
|
4 Application of the Fusion Protein Approach to other GPCRs |
|
|
476 | (2) |
|
|
478 | (1) |
|
|
479 | (2) |
|
26 Screening for Novel Constitutively Active CXCR2 Mutants and Their Cellular Effects |
|
|
481 | (18) |
|
|
|
|
|
|
|
|
482 | (1) |
|
2 Establishment of a Yeast System to Identify CXCR2 CAMs |
|
|
483 | (7) |
|
3 Establishment of a Mammalian System to Characterize CXCR2 CAMs |
|
|
490 | (5) |
|
|
495 | (4) |
|
27 A Method for Parallel Solid-Phase Synthesis of Iodinated Analogs of the Cannabinoid Receptor Type I (CB1) Inverse Agonist Rimonabant |
|
|
499 | (28) |
|
|
|
|
500 | (4) |
|
2 Concepts for Molecular Imaging |
|
|
504 | (1) |
|
3 Conventional Methods for Preparation of Radiolabeled Pharmaceuticals for Imaging the CB1 Receptor |
|
|
504 | (5) |
|
4 Parallel Solid-Phase Synthesis of lodinated Analogs of the CB1 Receptor Inverse Agonist Rimonabant |
|
|
509 | (5) |
|
|
514 | (9) |
|
|
523 | (4) |
|
28 Coexpression Systems as Models for the Analysis of Constitutive GPCR Activity |
|
|
527 | (32) |
|
|
|
|
528 | (1) |
|
2 Coexpression of GPCRs and Signaling Proteins: hH4R as Paradigm |
|
|
529 | (6) |
|
3 Investigation of GPCR Constitutive Activity with Coexpression Systems |
|
|
535 | (19) |
|
4 Application to Other Receptors |
|
|
554 | (2) |
|
|
556 | (1) |
|
|
556 | (3) |
|
29 Modeling and Simulation of Inverse Agonism Dynamics |
|
|
559 | (24) |
|
|
|
560 | (3) |
|
|
563 | (6) |
|
|
569 | (9) |
|
|
578 | (3) |
|
|
581 | (1) |
|
|
582 | (1) |
|
30 Design and Use of Constitutively Active STAT5 Constructs |
|
|
583 | (14) |
|
|
|
583 | (2) |
|
2 Design of Constitutively Active STAT5 Constructs |
|
|
585 | (4) |
|
3 Use of Constitutively Active STAT5 Constructs |
|
|
589 | (4) |
|
4 Concerns with the Use of Constitutively Active STAT5 Constructs |
|
|
593 | (2) |
|
|
595 | (1) |
|
|
595 | (2) |
|
31 In Vitro and In Vivo Assays of Protein Kinase CK2 Activity |
|
|
597 | (14) |
|
|
|
|
|
|
|
|
598 | (1) |
|
2 Monitoring of CK2 Catalytic Activity in Living Cells |
|
|
598 | (3) |
|
3 Assays of CK2 Subunit Interaction |
|
|
601 | (2) |
|
4 Visualization of CK2α-CK2β Interaction in Living Cells |
|
|
603 | (6) |
|
|
609 | (1) |
|
|
609 | (2) |
Author Index |
|
611 | (28) |
Subject Index |
|
639 | |